Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Achilles Therapeutics stock | $7.07

Learn how to easily invest in Achilles Therapeutics stock.

Achilles Therapeutics plc is a biotechnology business based in the US. Achilles Therapeutics shares (ACHL) are listed on the NASDAQ and all prices are listed in US Dollars. Achilles Therapeutics employs 153 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Achilles Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACHL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Achilles Therapeutics stock price (NASDAQ: ACHL)

Use our graph to track the performance of ACHL stocks over time.

Achilles Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$7.07
52-week range$5.45 - $18.95
50-day moving average $6.87
200-day moving average $9.87
Wall St. target price$19.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.11

Buy Achilles Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Achilles Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Achilles Therapeutics price performance over time

Historical closes compared with the close of $7.07 from 2021-10-18

1 week (2021-10-12) -20.20%
1 month (2021-09-17) 21.27%
3 months (2021-07-19) 10.30%
6 months (2021-04-19) -54.42%
1 year (2020-10-15) N/A
2 years (2019-10-15) N/A
3 years (2018-10-15) N/A
5 years (2016-10-15) N/A

Achilles Therapeutics financials

Gross profit TTM $0
Return on assets TTM -14.13%
Return on equity TTM -25.07%
Profit margin 0%
Book value $7.98
Market capitalisation $309 million

TTM: trailing 12 months

Shorting Achilles Therapeutics shares

There are currently 765,846 Achilles Therapeutics shares held short by investors – that's known as Achilles Therapeutics's "short interest". This figure is 29% up from 593,673 last month.

There are a few different ways that this level of interest in shorting Achilles Therapeutics shares can be evaluated.

Achilles Therapeutics's "short interest ratio" (SIR)

Achilles Therapeutics's "short interest ratio" (SIR) is the quantity of Achilles Therapeutics shares currently shorted divided by the average quantity of Achilles Therapeutics shares traded daily (recently around 216340.6779661). Achilles Therapeutics's SIR currently stands at 3.54. In other words for every 100,000 Achilles Therapeutics shares traded daily on the market, roughly 3540 shares are currently held short.

To gain some more context, you can compare Achilles Therapeutics's short interest ratio against those of similar companies.

However Achilles Therapeutics's short interest can also be evaluated against the total number of Achilles Therapeutics shares, or, against the total number of tradable Achilles Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Achilles Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Achilles Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0359% of the tradable shares (for every 100,000 tradable Achilles Therapeutics shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Achilles Therapeutics.

Find out more about how you can short Achilles Therapeutics stock.

Achilles Therapeutics share dividends

We're not expecting Achilles Therapeutics to pay a dividend over the next 12 months.

Achilles Therapeutics overview

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom. .

Frequently asked questions

What percentage of Achilles Therapeutics is owned by institutions?
Currently 50.84% of Achilles Therapeutics shares are held by institutions.
How many people work for Achilles Therapeutics?
Latest data suggests 153 work at Achilles Therapeutics.
When does the fiscal year end for Achilles Therapeutics?
Achilles Therapeutics's fiscal year ends in December.
Where is Achilles Therapeutics based?
Achilles Therapeutics's address is: 245 Hammersmith Road, London, United Kingdom, W6 8PW
What is Achilles Therapeutics's ISIN number?
Achilles Therapeutics's international securities identification number is: US00449L1026

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site